DPP4 and hepatocellular carcinoma: Although one study showed that thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B infection [31], there are relatively few on DPP-4 inhibitors in this group patient.